protocolSection identificationModule nctId: NCT06367751, orgStudyIdInfo id: 2024-00358; th23Kasenda, briefTitle: Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT), acronym: LIQPLAT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-10, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University Hospital, Basel, Switzerland, class: OTHER, collaborators name: Research Center for Clinical Neuroimmunology and Neuroscience Basel, descriptionModule briefSummary: The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel.Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with patients who did not receive ctDNA measurements (external comparator from registry AO_2023-00091).Blood samples will be drawn from the patients as part of routine care and ctDNA measurements will be performed on these samples., conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a trial using routinely collected health care data from an ongoing registry (AO_2023-00091) in cancer patients with advanced solid malignancies receiving first line systemic anti-cancer treatment for advanced disease. All patients will receive routine diagnostics, treatment and follow-up. All patients with a new cancer diagnosis will be assessed for eligibility based on the routinely collected information available in the registry. We will then randomly decide which eligible patients are invited to participate in the trial. If patients accept the invitation and intend to get a measurement of ctDNA, they have to provide written informed consent. The study comprises an external comparator arm with 75 (anticipated) cancer patients, and an active comparator arm with 150 (anticipated) cancer patients., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: ctDNA measurement, outcomesModule primaryOutcomes measure: Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment, primaryOutcomes measure: Patients in whom actionable alterations were identified in ctDNA analysis, primaryOutcomes measure: Turn-around time of ctDNA analysis, primaryOutcomes measure: ctDNA kinetics, secondaryOutcomes measure: Number of ctDNA testing results that were successfully made available to the molecular tumor board, secondaryOutcomes measure: Number of patients being positive for ctDNA and suspicious Clonal Hematopoiesis of Indeterminate Potential, secondaryOutcomes measure: Quality of life and physical function, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Survival rate 6 months, secondaryOutcomes measure: Survival rate 12 months, secondaryOutcomes measure: Time to next treatment line, secondaryOutcomes measure: Unplanned hospital admissions and emergency room visits, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Number of ctDNA analyses with a valid result, otherOutcomes measure: Patients being referred and recruited to a different interventional clinical trial, otherOutcomes measure: Tissue biopsies per patient, otherOutcomes measure: Imaging per patient, otherOutcomes measure: Blood products per patient, otherOutcomes measure: Cumulative doses of cancer drug treatments administered, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False